Frusemide 250 Mg/25 Ml Fresenius. 250 mg/25 m Solution for injection
PDF Leaflet Revision Date: 16 July 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Oliguria in acute or chronic renal failure.
Dosage (summary)
Up to 1 g daily, adjusted based on response; slow IV infusion.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended; crosses placenta and appears in breast milk.
Key Drug Interactions
- Digoxin
- NSAIDs
- Aminoglycosides
- ACE inhibitors
Contraindications
- Hypersensitivity to furosemide
- Hypovolaemia
- Severe hypokalaemia
- Pregnancy and lactation
Common side effects
- Hypokalaemia
- Dizziness
- Dehydration
- Tinnitus
Counselling Points
- Monitor fluid intake
- Regular electrolyte checks
- Avoid alcohol and CNS depressants
Serious warnings
- Risk of hypotension
- Electrolyte imbalances
- Potential for nephrotoxicity
Important Disclaimer
The Frusemide 250 Mg/25 Ml Fresenius. 250 mg/25 m Solution for injection professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
